Dr Reddy’s Laboratories Q4FY25 outcomes: Dr Reddy’s Laboratories, the nation’s main India-based pharmaceutical firm, launched its March quarter efficiency on Friday, Might 9, reporting a 22% year-on-year leap in consolidated internet revenue to ₹1,594 crore, beating Road estimates of ₹1,491 crore.
Income additionally exceeded estimates, coming in at ₹8,506 crore in comparison with ₹7,083 crore in the identical interval final yr, marking a development of 20%.
On the working entrance, EBITDA got here in at ₹2,975 crore, marking a 58.9% enchancment in comparison with ₹1,872 crore in Q4FY23, whereas margins expanded by 510 foundation factors to succeed in 29.1%. In the identical quarter of the earlier fiscal yr, the corporate had reported a margin of 24%.
